9.52
price down icon22.73%   -2.80
after-market アフターアワーズ: 9.53 0.010 +0.11%
loading
前日終値:
$12.32
開ける:
$9.145
24時間の取引高:
25.34M
Relative Volume:
3.40
時価総額:
$1.02B
収益:
$52.86M
当期純損益:
$-480.19M
株価収益率:
-2.0299
EPS:
-4.6899
ネットキャッシュフロー:
$-421.82M
1週間 パフォーマンス:
-24.56%
1か月 パフォーマンス:
-53.42%
6か月 パフォーマンス:
+30.59%
1年 パフォーマンス:
-40.50%
1日の値動き範囲:
Value
$8.96
$10.11
1週間の範囲:
Value
$8.96
$13.69
52週間の値動き範囲:
Value
$5.90
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1134)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
9.52 1.32B 52.86M -480.19M -421.82M -4.6899
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.47 105.61B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
657.53 67.99B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
442.70 58.19B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
854.65 52.40B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.70 39.60B 447.02M -1.18B -906.14M -6.1812

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Nov 07, 2025

Intellia Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Nov 07, 2025
pulisher
Nov 07, 2025

NTLA: Analyst Chardan Capital Lowers Price Target; Maintains Buy Rating | NTLA Stock News - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Nov 07, 2025
pulisher
Nov 07, 2025

Wells Fargo Lowers PT on Intellia Therapeutics (NTLA), Maintains Rating | NTLA Stock News - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

NTLA: RBC Capital Maintains Rating, Lowers Price Target by 36% | - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics patient death prompts FDA clinical hold on CRISPR heart disease trials - The Business Journals

Nov 07, 2025
pulisher
Nov 07, 2025

RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating - MarketScreener

Nov 07, 2025
pulisher
Nov 07, 2025

Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial - Genetic Engineering and Biotechnology News

Nov 07, 2025
pulisher
Nov 07, 2025

Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers - BioPharma Dive

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year - TipRanks

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics Says a Patient Died in Gene Editing Trial - Barron's

Nov 07, 2025
pulisher
Nov 07, 2025

Wedbush Maintains NTLA Rating, Lowers Price Target to $7 | NTLA Stock News - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

NTLA’s Trials Pause: A Trigger for Stock Decline? - StocksToTrade

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Tumbles After Patient Dies Following Crispr Treatment - Bloomberg.com

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - TradingView

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics stock price target lowered to $9 at RBC after patient death - Investing.com Canada

Nov 07, 2025
pulisher
Nov 07, 2025

NTLA's Analyst Rating Maintained but Price Target Lowered | NTLA Stock News - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

Patient with liver damage in Intellia trial dies - statnews.com

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - Clinical Trials Arena

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics (NTLA) Reports Strong Revenue Growth and S - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

Is It Too Late to Buy NTLA? - timothysykes.com

Nov 07, 2025
pulisher
Nov 07, 2025

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - AOL.com

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia shares fall after hospitalised CRISPR patient dies - pharmaphorum

Nov 07, 2025
pulisher
Nov 07, 2025

Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate - BioSpace

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics (NTLA) Shares Plunge After Phase 3 Trial S - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12 - MarketScreener

Nov 07, 2025
pulisher
Nov 07, 2025

JP Morgan Downgrades Intellia Therapeutics (NTLA) with Lower Pri - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia stock plunges after patient death (NTLA:NASDAQ) - Seeking Alpha

Nov 07, 2025
pulisher
Nov 07, 2025

Chart overlay techniques for tracking Intellia Therapeutics Inc.Forecast Cut & High Win Rate Trade Alerts - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

Patient hospitalised after receiving Intellia's CRISPR therapy dies - FirstWord Pharma

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics (NTLA) Faces Setback with FDA Hold on Key Trials - GuruFocus

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics stock rating maintained at Neutral by Baird - Investing.com India

Nov 07, 2025
pulisher
Nov 07, 2025

Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty - TipRanks

Nov 07, 2025
pulisher
Nov 07, 2025

Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan - TipRanks

Nov 07, 2025
pulisher
Nov 07, 2025

Transcript : Intellia Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener

Nov 07, 2025
pulisher
Nov 07, 2025

Patient dies after receiving Intellia's CRISPR therapy - Fierce Biotech

Nov 07, 2025
pulisher
Nov 07, 2025

JPMorgan downgrades Intellia Therapeutics stock on liver toxicity concerns - Investing.com

Nov 07, 2025
pulisher
Nov 07, 2025

How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Earnings Summary & Precise Buy Zone Identification - newser.com

Nov 07, 2025
pulisher
Nov 06, 2025

Intellia Trims Losses And Edges Toward Major Drug Launch - Finimize

Nov 06, 2025
pulisher
Nov 06, 2025

Patient in Intellia CRISPR trial dies after being hospitalized with liver injury - Endpoints News

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback - TipRanks

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics Third Quarter 2025 Financial Results Call - Intellia Therapeutics

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics Q3 2025 Earnings: EPS of -$0.99 and Revenue of $15.19 Million Meet Estimates - GuruFocus

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics Inc earnings beat by $0.09, revenue fell short of estimates - Investing.com

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Q3 net loss narrows - MarketScreener

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Nov 06, 2025
pulisher
Nov 06, 2025

Intellia (NASDAQ: NTLA) completes HAELO Phase 3 enrollment; topline mid-2026 - Stock Titan

Nov 06, 2025
pulisher
Nov 06, 2025

Will Intellia Therapeutics Inc. (38I) stock recover faster than industry2025 Volatility Report & AI Powered Market Trend Analysis - newser.com

Nov 06, 2025
pulisher
Nov 06, 2025

Does Intellia Therapeutics Inc. stock trade at a discount to peersWeekly Trade Summary & High Accuracy Investment Signals - fcp.pa.gov.br

Nov 06, 2025

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$38.56
price down icon 5.44%
$28.66
price down icon 0.62%
$105.98
price up icon 0.70%
$103.14
price down icon 0.20%
biotechnology ONC
$319.97
price down icon 3.73%
$189.70
price up icon 2.17%
大文字化:     |  ボリューム (24 時間):